MedPage Today November 6, 2025
Monthly drug prices slashed by hundreds in deal with drugmakers
Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with obesity, President Trump announced on Thursday.
“Until now, neither of these two popular drugs have been covered by Medicare for weight loss, and only rarely by Medicaid,” Trump said during a press conference in the Oval Office. “That ends starting today …. This will improve the health of millions and millions of Americans.”
As part of a new deal with the White House, doses of Novo Nordisk and Eli Lilly’s blockbuster drugs for patients without insurance will be priced at $350 through TrumpRx for a month’s supply — the GLP-1 receptor agonists currently carry...
Today's Sponsors
Today's Sponsor